Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas

[1]  E. Jonasch,et al.  Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis , 2021, Nature Medicine.

[2]  R. Motzer,et al.  Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma , 2021, Clinical Cancer Research.

[3]  Ling Yang,et al.  Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma , 2021, Clinical Cancer Research.

[4]  Mark W. Ball,et al.  Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase–deficient renal cancer , 2021, Science Signaling.

[5]  P. Hegde,et al.  Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. , 2020, Cancer cell.

[6]  Mark W. Ball,et al.  Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. , 2020, Journal of Clinical Oncology.

[7]  Alexander V Penson,et al.  Phase and context shape the function of composite oncogenic mutations , 2020, Nature.

[8]  G. Stewart,et al.  Oncometabolites in renal cancer , 2019, Nature Reviews Nephrology.

[9]  M. Zhou,et al.  A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients , 2019, The American journal of surgical pathology.

[10]  R. Heshmat,et al.  The Impact Of Succinate Dehydrogenase Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review , 2019, OncoTargets and therapy.

[11]  J. Cheville,et al.  Incidence of Succinate Dehydrogenase and Fumarate Hydratase-Deficient Renal Cell Carcinoma Based on Immunohistochemical Screening with SDHA/SDHB and FH/2SC. , 2019, Human pathology.

[12]  N. Socci,et al.  Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.

[13]  O. Dekkers,et al.  Increased Mortality in SDHB but Not in SDHD Pathogenic Variant Carriers , 2019, Cancers.

[14]  M. Bonert,et al.  SDH-deficient renal cell carcinoma – clinical, pathologic and genetic correlates: a case report , 2018, BMC Urology.

[15]  B. Shuch,et al.  Krebs Cycle-Deficient Hereditary Cancer Syndromes are Defined by Homologous Recombination DNA Repair Defects , 2018, Nature Genetics.

[16]  David C Wedge,et al.  Principles of Reconstructing the Subclonal Architecture of Cancers. , 2017, Cold Spring Harbor perspectives in medicine.

[17]  S. Dhanasekaran,et al.  Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes , 2017, The American journal of surgical pathology.

[18]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[19]  E. Papaemmanuil,et al.  Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal SDHB-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect , 2017, JCO precision oncology.

[20]  N. Schultz,et al.  Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets , 2016, Nature Communications.

[21]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[22]  K. Garg,et al.  Immunohistochemistry for 2-Succinocysteine (2SC) and Fumarate Hydratase (FH) in Cutaneous Leiomyomas May Aid in Identification of Patients With HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome) , 2016, The American journal of surgical pathology.

[23]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[24]  A. Iafrate,et al.  Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia , 2015 .

[25]  A. Vazquez,et al.  Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis , 2015, Nature Cell Biology.

[26]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[27]  Nicolai J. Birkbak,et al.  Clonal status of actionable driver events and the timing of mutational processes in cancer evolution , 2015, Science Translational Medicine.

[28]  J. McKenney,et al.  Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma: A Morphologically Distinct Entity , 2014, The American journal of surgical pathology.

[29]  W. Linehan,et al.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment , 2014, Familial Cancer.

[30]  M. Berger,et al.  Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome–associated Renal Cancer: Recognition of the Syndrome by Pathologic Features and the Utility of Detecting Aberrant Succination by Immunohistochemistry , 2014, The American journal of surgical pathology.

[31]  L. Lipton,et al.  Germline SDHC mutation presenting as recurrent SDH deficient GIST and renal carcinoma. , 2013, Pathology.

[32]  Laurence Amar,et al.  SDH mutations establish a hypermethylator phenotype in paraganglioma. , 2013, Cancer cell.

[33]  C. Ludwig,et al.  A Role for Cytosolic Fumarate Hydratase in Urea Cycle Metabolism and Renal Neoplasia , 2013, Cell reports.

[34]  P. Szlosarek,et al.  Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells , 2013, Cancer & metabolism.

[35]  W. Linehan,et al.  The metabolic basis of kidney cancer. , 2013, Seminars in cancer biology.

[36]  D. Margolis,et al.  Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. , 2012, Blood.

[37]  Hui Yang,et al.  Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. , 2012, Genes & development.

[38]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[39]  A. Gill,et al.  Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. , 2011, The New England journal of medicine.

[40]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[41]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[42]  M. Amin,et al.  Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma , 2015, Modern Pathology.

[43]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.